ORY Stock Overview
A clinical stage biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS disorders. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Oryzon Genomics S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €1.62 |
| 52 Week High | €2.39 |
| 52 Week Low | €1.55 |
| Beta | 0.65 |
| 11 Month Change | -9.70% |
| 3 Month Change | -8.78% |
| 1 Year Change | -19.40% |
| 33 Year Change | -48.24% |
| 5 Year Change | -40.00% |
| Change since IPO | -64.78% |
Recent News & Updates
Recent updates
Growth Investors: Industry Analysts Just Upgraded Their Oryzon Genomics S.A. (BME:ORY) Revenue Forecasts By 54%
Oct 03
Oryzon Genomics S.A. (BME:ORY) Screens Well But There Might Be A Catch
Jun 09Is Oryzon Genomics (BME:ORY) Using Too Much Debt?
Apr 04Industry Analysts Just Made A Dazzling Upgrade To Their Oryzon Genomics S.A. (BME:ORY) Revenue Forecasts
Jul 24Is Oryzon Genomics (BME:ORY) Weighed On By Its Debt Load?
May 01Oryzon Genomics (BME:ORY) Has Debt But No Earnings; Should You Worry?
Feb 26If You Had Bought Oryzon Genomics (BME:ORY) Shares A Year Ago You'd Have Earned 18% Returns
Jan 04
Shareholder Returns
| ORY | ES Biotechs | ES Market | |
|---|---|---|---|
| 7D | -4.8% | -1.2% | 0.2% |
| 1Y | -19.4% | -4.0% | 17.0% |
Return vs Industry: ORY underperformed the Spanish Biotechs industry which returned -4% over the past year.
Return vs Market: ORY underperformed the Spanish Market which returned 17% over the past year.
Price Volatility
| ORY volatility | |
|---|---|
| ORY Average Weekly Movement | 3.4% |
| Biotechs Industry Average Movement | 7.8% |
| Market Average Movement | 2.9% |
| 10% most volatile stocks in ES Market | 5.4% |
| 10% least volatile stocks in ES Market | 0.6% |
Stable Share Price: ORY has not had significant price volatility in the past 3 months compared to the Spanish market.
Volatility Over Time: ORY's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 44 | Carlos Manuel Arjol | www.oryzon.com |
Oryzon Genomics S.A., a clinical stage biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS disorders. Its clinical phase compounds include iadademstat (ORY-1001), a selective LSD1 inhibitor that is in Phase II trials for oncology; and vafidemstat (ORY-2001), a CNS-optimized LSD1 inhibitor, which is in Phase II trials for the treatment of CNS and psychiatric diseases. Its product candidates also comprise ORY-3001, an LSD1 inhibitor that is in preclinical development for the treatment of non-oncological diseases.
Oryzon Genomics S.A. Fundamentals Summary
| ORY fundamental statistics | |
|---|---|
| Market cap | €104.36m |
| Earnings (TTM) | -€4.33m |
| Revenue (TTM) | €15.04m |
6.8x
P/S Ratio-23.6x
P/E RatioIs ORY overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ORY income statement (TTM) | |
|---|---|
| Revenue | US$15.83m |
| Cost of Revenue | US$271.80k |
| Gross Profit | US$15.56m |
| Other Expenses | US$20.11m |
| Earnings | -US$4.56m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.072 |
| Gross Margin | 98.28% |
| Net Profit Margin | -28.78% |
| Debt/Equity Ratio | 20.8% |
How did ORY perform over the long term?
See historical performance and comparison